Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Good outcome of living donor liver transplantation in drug-induced acute liver failure: A single-center experience.

Choudhary NS, Saigal S, Saraf N, Rastogi A, Goja S, Bhangui P, Vohra V, Govil D, Soin AS.

Clin Transplant. 2017 Mar;31(3). doi: 10.1111/ctr.12907.

PMID:
28054388
2.

Orlistat-induced fulminant hepatic failure.

Sall D, Wang J, Rashkin M, Welch M, Droege C, Schauer D.

Clin Obes. 2014 Dec;4(6):342-7. doi: 10.1111/cob.12075. Epub 2014 Sep 29.

PMID:
25826164
3.

The effect of ezetimibe on NAFLD.

Averna M.

Atheroscler Suppl. 2015 Feb;17:27-34. doi: 10.1016/S1567-5688(15)50007-X. Review.

PMID:
25659874
4.

Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications.

Halpern B, Halpern A.

Expert Opin Drug Saf. 2015 Feb;14(2):305-15. doi: 10.1517/14740338.2015.994502. Epub 2015 Jan 7. Review.

PMID:
25563411
5.

Benefit-risk assessment of orlistat in the treatment of obesity.

Sumithran P, Proietto J.

Drug Saf. 2014 Aug;37(8):597-608. doi: 10.1007/s40264-014-0210-7. Review.

PMID:
25064699
6.

Antiobese effects of capsaicin-chitosan microsphere (CCMS) in obese rats induced by high fat diet.

Tan S, Gao B, Tao Y, Guo J, Su ZQ.

J Agric Food Chem. 2014 Feb 26;62(8):1866-74. doi: 10.1021/jf4040628. Epub 2014 Feb 14.

PMID:
24479662
7.

Honeysuckle anthocyanin supplementation prevents diet-induced obesity in C57BL/6 mice.

Wu T, Yu Z, Tang Q, Song H, Gao Z, Chen W, Zheng X.

Food Funct. 2013 Nov;4(11):1654-61. doi: 10.1039/c3fo60251f.

PMID:
24081320
8.

Orlistat: should we worry about liver inflammation?

Wilding J.

BMJ. 2013 Apr 30;346:f2777. doi: 10.1136/bmj.f2777. No abstract available.

PMID:
23633008
9.

Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink.

Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L.

BMJ. 2013 Apr 12;346:f1936. doi: 10.1136/bmj.f1936.

10.

Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs.

Xiao D, Shi D, Yang D, Barthel B, Koch TH, Yan B.

Biochem Pharmacol. 2013 Feb 1;85(3):439-47. doi: 10.1016/j.bcp.2012.11.026. Epub 2012 Dec 7.

11.

An integrated analysis of liver safety data from orlistat clinical trials.

Morris M, Lane P, Lee K, Parks D.

Obes Facts. 2012;5(4):485-94. doi: 10.1159/000341589. Epub 2012 Jul 23.

12.

Orlistat: hepatitis and oxalate nephropathy.

[No authors listed]

Prescrire Int. 2012 Mar;21(125):71. No abstract available.

PMID:
22428191
13.

Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial.

Smith SR, Stenlof KS, Greenway FL, McHutchison J, Schwartz SM, Dev VB, Berk ES, Kapikian R.

Obesity (Silver Spring). 2011 Sep;19(9):1796-803. doi: 10.1038/oby.2011.143. Epub 2011 Jun 30.

14.

Orlistat-associated adverse effects and drug interactions: a critical review.

Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS.

Drug Saf. 2008;31(1):53-65. Review.

PMID:
18095746
15.

Severe hepatic injury caused by orlistat.

Umemura T, Ichijo T, Matsumoto A, Kiyosawa K.

Am J Med. 2006 Aug;119(8):e7. No abstract available.

PMID:
16887401
16.

Orlistat (Xenical)-induced subacute liver failure.

Thurairajah PH, Syn WK, Neil DA, Stell D, Haydon G.

Eur J Gastroenterol Hepatol. 2005 Dec;17(12):1437-8. No abstract available.

PMID:
16292105
17.

Orlistat treatment in obese prepubertal children: a pilot study.

Norgren S, Danielsson P, Jurold R, Lötborn M, Marcus C.

Acta Paediatr. 2003 Jun;92(6):666-70.

PMID:
12856974
18.

[A case of acute cholestatic hepatitis associated with Orlistat].

Kim DH, Lee EH, Hwang JC, Jeung JH, Kim DY, Cheong JY, Cho SW, Kim YB.

Taehan Kan Hakhoe Chi. 2002 Sep;8(3):317-20. Korean.

PMID:
12499790
19.
20.

[Hepatotoxicity of medications].

Barbare JC, Imbert A, Benkirane A.

Presse Med. 2001 Apr 14;30(14):673-6. Review. French.

PMID:
11360729

Supplemental Content

Loading ...
Support Center